Document is current

Article History

Received: 21 October 2025

Accepted: 21 December 2025

First Online: 8 January 2026

Declarations

:

: LIGHT has been approved by the medical ethical committee of MUMC+ (NL86513.068.24) and is registered at Dutch trial register OMON (NL-OMON57198) and ClinicalTrials.gov (NCT06832761, registration date February 18th 2025) and is conducted in line with the Declaration of Helsinki. All participants in the study provide written informed consent at the baseline study visit.

: Not applicable.

: RH received outside this study consulting fees in the past 36 months from Lilly Nederland and from the Institute for Medical Technology Assessment (paid to institution). MV received outside this study funding in the past 36 months from ZonMW, Gieskes-Strijbisfonds, Alzheimer Onderzoeksfonds Limburg, Health~Holland, Topsector Life Sciences & Health and Stichting Alzheimer Nederland (paid to institution). SS received outside this study funding in the past 36 months from ZonMW, Health~Holland, Topsector Life Sciens & Health, Innovative Health Initiative Joint Undertaking (IHI JU), NWO and JPND (paid to the institution). SS provided consultancy services for Nationale Nederlanden Ventures, Prothena Biosciences, Aribio Co LTD, Cogstate LTD (paid to institution). Research programs of WF have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Noaber foundation, Pieter Houbolt Fonds, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Eli-Lilly-NL, Fujifilm, Eisai, Combinostics. As of 1-11-2025, WF is executive director at Alzheimer Nederland, Amersfoort the Netherlands. Before 1-11-2025, research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Noaber foundation, Pieter Houbolt Fonds, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Eli-Lilly-NL, Fujifilm, Eisai, Combinostics. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). Before 1-11-2025, WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF has been consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France, Nationale Nederlanden Ventures. WF has participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. 2024-2025, WF has been member of the steering committee of phase 3 EVOKE/EVOKE+ studies (NovoNordisk). In 2025, WF has been member of the steering committee op phase 3 Trontinemab study (Roche). All funding has been paid to Amsterdam UMC. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF was associate editor at Brain 2021-2025. WF is chair of the Scientific Leadership Group of InRAD. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut. MZ received outside this study funding from ZonMw‐Memorabel (project no 73305095003), Alzheimer Nederland, Hersenstichting (Dutch Brain Foundation) and Amsterdam Neuroscience; and is trial site coordinator of sponsor-initiated studies with AviadoBio and TheriniBio (all paid to institution). All other authors have nothing to disclose.